Iovance's Amtagvi Shows Stronger Real-World Response Rates in Advanced Melanoma
Event summary
- Iovance Biotherapeutics presented real-world data showing Amtagvi achieved a 44% objective response rate (ORR) in 41 patients with advanced melanoma.
- Response rates were higher with earlier treatment: 52% ORR after two or fewer lines of therapy vs. 33% after three or more.
- The data was highlighted at the 2026 Tandem Meetings of ASTCT and CIBMTR in Salt Lake City.
- Amtagvi's real-world ORR improved upon the 31% ORR seen in the C-144-01 clinical trial that supported its FDA accelerated approval in February 2024.
The big picture
Iovance's real-world data reinforces Amtagvi's potential as a frontline treatment for advanced melanoma, addressing an unmet need where over half of patients progress within a year of standard care. The results position Amtagvi favorably against other cellular therapies and highlight the strategic importance of early intervention in solid tumor treatments. With ongoing Phase 3 trials and a focus on manufacturing scalability, Iovance is betting on TIL therapies to redefine oncology treatment paradigms.
What we're watching
- Treatment Timing
- How earlier Amtagvi treatment will affect adoption rates and patient outcomes in advanced melanoma.
- Regulatory Pathway
- Whether the real-world data will support expanded approvals or influence reimbursement discussions.
- Competitive Positioning
- The pace at which Iovance can establish Amtagvi as a best-in-class therapy amid emerging TIL competitors.
Related topics